Can three-dimensional MRI help us measure potential risks for stroke associated with an intraplaque hemorrhage? We are rapidly learning more about the significance of intraplaque hemorrhage, and its role in cardiac and cerebrovascular disease. A better look at potential trouble spots could allow for earlier detection of an impending event, even in relatively asymptomatic individuals. Dr. Alan Moody, professor in the department of medical imaging at the University of Toronto Faculty of Medicine, shares his perspective on 3D MRI as an important tool to lead us in this direction. On a related note, Dr. Moody also provides some insight on what we can do patients with an intraplaque hemorrhage who is already on a statin, aspirin or another therapy to reduce their risk of having this happen again. Dr. Larry Kaskel hosts.
3D Imaging for Stroke-Inducing Carotid Artery Disease

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Can three-dimensional MRI help us measure potential risks for stroke associated with an intraplaque hemorrhage? We are rapidly learning more about the significance of intraplaque hemorrhage, and its role in cardiac and cerebrovascular disease. A better look at potential trouble spots could allow for earlier detection of an impending event, even in relatively asymptomatic individuals. Dr. Alan Moody, professor in the department of medical imaging at the University of Toronto Faculty of Medicine, shares his perspective on 3D MRI as an important tool to lead us in this direction. On a related note, Dr. Moody also provides some insight on what we can do patients with an intraplaque hemorrhage who is already on a statin, aspirin or another therapy to reduce their risk of having this happen again. Dr. Larry Kaskel hosts.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis
Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
HF Management for Patients with Comorbid Conditions
Level Up Your Skills: Tailoring Management of HF
Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
How Do We Translate Real-World AF Data Into Everyday Clinical Practice?
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?